However, for the clinical application of CEA or CA19-9 alone, only 30% of CCA patients exhibit elevated CEA levels20 and CA19-9 is often falsely elevated in benign biliary disease or cholangitis21. This evidence concerns the gene CEACAM5 and cholangiocarcinoma.